The role of angiotensinconverting enzyme inhibitors in the treatment of hypertension

被引：6

作者：

Sleight P. ^{[1
]}

机构：

[1] Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital

来源：

Current Cardiology Reports | 2001年 / 3卷 / 6期

关键词：

Calcium Channel Blocker; Ramipril; United Kingdom Prospective Diabetes Study; Heart Outcome Prevention Evaluation; Heart Outcome Prevention Evaluation Study;

D O I：

10.1007/s11886-001-0074-1

中图分类号：

学科分类号：

摘要：

Angiotensin-converting enzyme (ACE) inhibitors continue to find new uses. The Heart Outcomes Prevention Evaluation study has demonstrated their wide application as a preventive measure for patients at high risk of cardiovascular disease, but the available clinical trials in hypertensive subjects do not so far suggest any clear superiority over conventional treatment. The available trials may have been underpowered to detect non-blood pressure-related benefits on smooth muscle growth, endothelial function, left ventricular hypertrophy, and plaque rupture, when used in relatively low-risk subjects with uncomplicated hypertension. Clinical trials have also shown that two or more drugs are needed to lower blood pressure even to 140/90. Few patients have uncomplicated hypertension, so the choice of their drugs will be powerfully influenced by their other clinical problems. Nevertheless, there is a strong case for an attack on the renin-angiotensin system. Whether this will be by ACE inhibition, angiotensin-II receptor blockade, or both, is the subject of current clinical trials. Copyright © 2001 by Current Science Inc.

引用

页码：511 / 518

页数：7

共 22 条

[1]

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39, Br Med J, 317, pp. 713-720, (1998)

[2]

Hansson L., Zanchetti A., Carruthers S.G., Et al., Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet, 351, pp. 1755-1762, (1998)

[3]

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials, Lancet, 355, pp. 1955-1964, (2000)

[4]

Furberg C.F., Psaty B.M., Meyer J.V., Nifedipine: Dose-related increase in mortality in patients with coronary heart disease, Circulation, 92, pp. 1326-1331, (1995)

[5]

Pahor M., Kritchevsky S.B., Zuccala G., Et al., Diabetes and risk of adverse events with calcium antagonists, Diabetes Care, 21, pp. 193-194, (1998)

[6]

Hansson L., Lindholm L., Ekbom T., Et al., Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study, Lancet, 354, pp. 1751-1756, (1999)

[7]

Brown M.J., Palmer C.R., Castaigne A., Et al., Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT), Lancet, 356, pp. 366-372, (2000)

[8]

Hansson L., Hedner T., Lund-Johansen P., Et al., Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study, Lancet, 356, pp. 359-365, (2000)

[9]

Beevers D.G., Sleight P., Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: Is there a risk?, Br Med J, 312, pp. 1143-1145, (1996)

[10]

Dahlof B., Pennert K., Hansson L., Reversal of left ventricular hypertrophy in hypertensive patients. A meta analysis of 109 treatment studies, Am J Hypertens, 5, pp. 95-110, (1992)

← 1 2 3 →